Head and Neck Cancer Market By Drug Class (EGFR Inhibitors, Mitotic, Inhibitors, Anti-PD-1 Monoclonal Antibodies, and Others (Docetaxel, fluorouracil)), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and E-commerce), and By Region - Trends, Analysis and Forecast till 2034

The head and neck cancer market is expected to reach US$2.9 billion by 2034, having grown to US$1.8 billion in 2024 at a compound annual growth rate of 5.40%.

A collection of tumors that arise in the tissues of the head and neck area is referred to as head and neck cancer. This encompasses the salivary glands, nasal cavity, sinuses, voice box (larynx), oral cavity (mouth), and throat. Cancers of the head and neck are prevalent and can affect a variety of structures in this region, resulting in a range of symptoms and treatment modalities.

The prevalence of head and neck cancer has been steadily rising over time, making it a primary global health concern. Head and neck cancer is becoming more common due to several factors, including environmental exposures, HPV infection, and tobacco and alcohol usage. The head and neck cancer market is predicted to rise due to this expanding patient population.